Michael Yee
Stock Analyst at UBS
(3.99)
# 597
Out of 5,182 analysts
118
Total ratings
48.19%
Success rate
13.6%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgrades: Buy | $185 → $225 | $183.09 | +22.89% | 7 | Apr 22, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $90 → $60 | $68.87 | -12.88% | 3 | Apr 21, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Buy | $45 | $19.15 | +134.99% | 1 | Apr 21, 2026 | |
| AMGN Amgen | Maintains: Buy | $390 → $400 | $342.67 | +16.73% | 8 | Apr 13, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $130 → $145 | $111.54 | +30.00% | 1 | Apr 13, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $27 | $26.98 | +0.07% | 2 | Apr 13, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $50 → $75 | $81.21 | -7.65% | 3 | Apr 6, 2026 | |
| KOD Kodiak Sciences | Maintains: Buy | $50 → $80 | $44.58 | +79.45% | 5 | Mar 27, 2026 | |
| SDGR Schrödinger | Maintains: Neutral | $18 → $13 | $11.94 | +8.88% | 4 | Mar 17, 2026 | |
| NUVB Nuvation Bio | Maintains: Neutral | $10 → $7 | $4.52 | +54.87% | 5 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $115 | - | - | 2 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $230 | $198.10 | +16.10% | 2 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $535 → $545 | $427.33 | +27.54% | 6 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $155 | $128.86 | +20.29% | 5 | Jan 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $50 | $29.51 | +69.43% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $25 | $20.27 | +23.33% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $24 → $55 | $28.92 | +90.18% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $3 → $12 | $5.13 | +133.92% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $13.47 | +271.20% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $46.67 | +28.56% | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.51 | +99.43% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $15.18 | +196.44% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $31.20 | +92.31% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $29.11 | -3.80% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.26 | +254.77% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $21.85 | +60.18% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.45 | +210.08% | 2 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $46 → $65 | $58.18 | +11.72% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $1,080 → $1,250 | $875.46 | +42.78% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $3 | $1.61 | +86.34% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $55 | $48.13 | +14.27% | 8 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $404.52 | -4.83% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.86 | -48.81% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $14.03 | +42.55% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.98 | +1,415.15% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $11.15 | +169.06% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $28.00 | +328.65% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $127.39 | -76.45% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $23.81 | +223.39% | 2 | Nov 8, 2018 |
Biogen
Apr 22, 2026
Upgrades: Buy
Price Target: $185 → $225
Current: $183.09
Upside: +22.89%
AnaptysBio
Apr 21, 2026
Maintains: Buy
Price Target: $90 → $60
Current: $68.87
Upside: -12.88%
First Tracks Biotherapeutics
Apr 21, 2026
Initiates: Buy
Price Target: $45
Current: $19.15
Upside: +134.99%
Amgen
Apr 13, 2026
Maintains: Buy
Price Target: $390 → $400
Current: $342.67
Upside: +16.73%
Merck & Co.
Apr 13, 2026
Maintains: Buy
Price Target: $130 → $145
Current: $111.54
Upside: +30.00%
Pfizer
Apr 13, 2026
Maintains: Neutral
Price Target: $25 → $27
Current: $26.98
Upside: +0.07%
Oruka Therapeutics
Apr 6, 2026
Maintains: Buy
Price Target: $50 → $75
Current: $81.21
Upside: -7.65%
Kodiak Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $50 → $80
Current: $44.58
Upside: +79.45%
Schrödinger
Mar 17, 2026
Maintains: Neutral
Price Target: $18 → $13
Current: $11.94
Upside: +8.88%
Nuvation Bio
Mar 3, 2026
Maintains: Neutral
Price Target: $10 → $7
Current: $4.52
Upside: +54.87%
Feb 24, 2026
Downgrades: Neutral
Price Target: $100 → $115
Current: -
Upside: -
Feb 5, 2026
Maintains: Neutral
Price Target: $240 → $230
Current: $198.10
Upside: +16.10%
Jan 26, 2026
Maintains: Buy
Price Target: $535 → $545
Current: $427.33
Upside: +27.54%
Jan 26, 2026
Maintains: Buy
Price Target: $145 → $155
Current: $128.86
Upside: +20.29%
Jan 7, 2026
Assumes: Buy
Price Target: $50
Current: $29.51
Upside: +69.43%
Jan 7, 2026
Assumes: Buy
Price Target: $25
Current: $20.27
Upside: +23.33%
Jan 7, 2026
Assumes: Buy
Price Target: $24 → $55
Current: $28.92
Upside: +90.18%
Jan 7, 2026
Assumes: Buy
Price Target: $3 → $12
Current: $5.13
Upside: +133.92%
Jan 7, 2026
Initiates: Buy
Price Target: $50
Current: $13.47
Upside: +271.20%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $46.67
Upside: +28.56%
Jan 7, 2026
Initiates: Buy
Price Target: $7
Current: $3.51
Upside: +99.43%
Jan 7, 2026
Initiates: Buy
Price Target: $45
Current: $15.18
Upside: +196.44%
Jan 7, 2026
Initiates: Buy
Price Target: $60
Current: $31.20
Upside: +92.31%
Jan 7, 2026
Initiates: Neutral
Price Target: $28
Current: $29.11
Upside: -3.80%
Jan 7, 2026
Initiates: Buy
Price Target: $8
Current: $2.26
Upside: +254.77%
Jan 7, 2026
Initiates: Buy
Price Target: $35
Current: $21.85
Upside: +60.18%
Jan 7, 2026
Initiates: Buy
Price Target: $20
Current: $6.45
Upside: +210.08%
Jan 7, 2026
Upgrades: Buy
Price Target: $46 → $65
Current: $58.18
Upside: +11.72%
Jan 7, 2026
Assumes: Buy
Price Target: $1,080 → $1,250
Current: $875.46
Upside: +42.78%
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $1.61
Upside: +86.34%
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $48.13
Upside: +14.27%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $404.52
Upside: -4.83%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.86
Upside: -48.81%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $14.03
Upside: +42.55%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.98
Upside: +1,415.15%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $11.15
Upside: +169.06%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $28.00
Upside: +328.65%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $127.39
Upside: -76.45%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $23.81
Upside: +223.39%